Predicting Progression of Developing Myeloma in a High-Risk Screened Population

Launched by TEL-AVIV SOURASKY MEDICAL CENTER · Apr 20, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how to predict and possibly prevent the progression of certain blood conditions, specifically monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), in people who are at high risk. Researchers believe that by identifying these conditions early and studying how they develop, they can create better strategies to improve patients' health and survival.

To participate in this study, individuals must be at least 30 years old and have a close family member with a related blood condition, or be at least 18 years old with multiple relatives affected. Participants will need to give their consent to use their health information for research, which they can withdraw at any time. Those who are currently diagnosed with cancer or are pregnant are not eligible. If you join the trial, you can expect to provide data and samples that will help researchers learn more about these conditions and how to manage them effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Must meet criteria of the high-risk population as described with one of the below criteria
• • ≥ 30 years AND
• • first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.
• • OR
• • Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer '
• • Voluntary written informed consent must be given with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
• Exclusion Criteria:
• • • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.
• • Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia
• • Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test.